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AbstrAct
Objective
To evaluate the duration of prescriptions for 
antibiotic treatment for common infections in English 
primary care and to compare this with guideline 
recommendations.
Design
Cross sectional study.
setting
General practices contributing to The Health 
Improvement Network database, 2013-15.
ParticiPants
931 015 consultations that resulted in an antibiotic 
prescription for one of several indications: acute 
sinusitis, acute sore throat, acute cough and 
bronchitis, pneumonia, acute exacerbation of chronic 
obstructive pulmonary disease (COPD), acute otitis 
media, acute cystitis, acute prostatitis, pyelonephritis, 
cellulitis, impetigo, scarlet fever, and gastroenteritis.
Main OutcOMe Measures
The main outcomes were the percentage of antibiotic 
prescriptions with a duration exceeding the guideline 
recommendation and the total number of days beyond 
the recommended duration for each indication.
results
The most common reasons for antibiotics being 
prescribed were acute cough and bronchitis (386 972, 
41.6% of the included consultations), acute sore 
throat (239 231, 25.7%), acute otitis media (83 054, 
8.9%), and acute sinusitis (76 683, 8.2%). Antibiotic 
treatments for upper respiratory tract indications and 
acute cough and bronchitis accounted for more than 
two thirds of the total prescriptions considered, and 
80% or more of these treatment courses exceeded 
guideline recommendations. Notable exceptions 
were acute sinusitis, where only 9.6% (95% 
confidence interval 9.4% to 9.9%) of prescriptions 
exceeded seven days and acute sore throat where 
only 2.1% (2.0% to 2.1%) exceeded 10 days (recent 
guidance recommends five days). More than half 
of the antibiotic prescriptions were for longer than 
guidelines recommend for acute cystitis among 
females (54.6%, 54.1% to 55.0%). The percentage of 
antibiotic prescriptions exceeding the recommended 
duration was lower for most non-respiratory 
infections. For the 931 015 included consultations 
resulting in antibiotic prescriptions, about 1.3 million 
days were beyond the durations recommended by 
guidelines.
cOnclusiOn
For most common infections treated in primary care, 
a substantial proportion of antibiotic prescriptions 
have durations exceeding those recommended in 
guidelines. Substantial reductions in antibiotic 
exposure can be accomplished by aligning antibiotic 
prescription durations with guidelines.
Introduction
Many countries, including the United Kingdom, are 
trying to tackle antibiotic resistance by reducing 
unnecessary or inappropriate prescribing.1-3 The clear 
link between antibiotic prescribing and resistance 
at the individual4 5 and population level6 indicates 
that reducing antibiotic prescribing might decrease—
or should at least stabilise—levels of antibiotic 
resistance.7-9 Previous work has reported substantial 
over-prescribing of antibiotics in primary care in the 
UK1 10 11 and elsewhere.3 12 Reducing unnecessary 
antibiotic use can be achieved by starting antibiotic 
treatments only when clearly indicated,1 11 changing 
the choice of drug for specific conditions,6 or avoiding 
unnecessarily long durations of treatment.13 Strategies 
to control antibiotic overuse in primary care focus 
on the initial prescribing decision (whether to treat, 
and choice of agent) because it is not routinely 
possible to reassess patients who start antibiotics.14 
Little attention has been given to the possibility 
of reducing antibiotic overuse in primary care by 
minimising unnecessarily prolonged treatment.15 
Historically, general practitioners have been taught 
that antibiotic courses should be long enough to 
prevent the development of antibiotic resistance in 
the infection that is being treated, based on evidence 
of the emergence of resistance frequently being 
WhAt Is AlreAdy knoWn on thIs topIc
A clear causal link exists between antibiotic exposure and antibiotic resistance
Strategies to reduce antibiotic use in primary care focus on decisions to start 
treatment
It is not known to what extent excessive treatment duration contributes to 
antibiotic overuse in primary care
WhAt thIs study Adds
For many common infections treated in primary care, a substantial proportion 
of antibiotic prescriptions have durations that exceed those recommended in 
guidelines
Rates of treatment duration beyond guidelines are highest for respiratory tract 
infections and are similar among patients with and without comorbidities
Substantial reductions in antibiotic use in primary care could be achieved by 
closer compliance with recommended treatment durations
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related to suboptimal dosing of penicillins in the 
treatment of Streptococcus pneumoniae.16 However, 
current concerns primarily relate to the development 
of resistance in common commensal bacteria, rather 
than in the ones causing the infections, where there 
is increasing evidence that the opposite is true—
the longer the exposure to antibiotic the greater the 
development of antibiotic resistance, which then 
leads to a greater risk of resistance in subsequent 
infections.17 18 Overuse of antibiotics not only 
contributes to increased antibiotic resistance levels but 
also puts patients at risk of side effects. Common side 
effects include diarrhoea, rash, and candidiasis.19 20 
Cumulative exposure to antibiotics has been identified 
as a major risk factor for Clostridium difficile infection, 
highlighting the need to reduce the duration of 
treatment where possible.21 22 Although less common, 
other serious side effects are important reasons to 
minimise exposure to particular antibiotics. For 
example, macrolides are associated with an increased 
risk of serious ventricular arrhythmias and increased 
risk of sudden cardiac death.23 Moreover, the US Food 
and Drug Administration recently strengthened its 
warning about fluoroquinolones potentially causing 
substantial decreases in blood sugar levels and mental 
health side effects.24
Evidence about the contribution of excessive 
treatment duration to antibiotic overuse in primary 
care is limited. A recent study from the US showed that 
more than two thirds of antibiotic courses for acute 
sinusitis in adults were 10 days or longer, whereas the 
Infectious Disease Society of America recommends 
treatment of uncomplicated cases for five to seven 
days.25 A small study from the Manitoba region in 
Canada, that focused on urinary tract infection, 
pharyngitis, skin or soft tissue infections, and 
pneumonia estimated that 15% of prescriptions with 
the appropriate antibiotic were for treatments longer 
than guideline based recommendations.26
An up-to-date picture on prescribed antibiotic 
durations for common infections in English primary 
care is lacking. Such an overview is especially relevant 
given the increasing evidence from randomised 
controlled trials and meta-analyses that shorter 
antibiotic courses clear infection comparable to longer 
courses, while minimising selection, proliferation, 
and spread of antibiotic resistant bacteria and the 
likelihood of side effects from antibiotic use.18 27 28
We therefore assessed the extent to which durations 
of antibiotic courses prescribed for common infections 
in English primary care are in line with relevant 
guidelines. If substantial proportions of antibiotic 
prescriptions are longer than recommended, this 
would indicate that there is potential to safely reduce 
total antibiotic use simply by better application of 
guidelines in clinical practice.
Methods
Data were obtained from The Health Improvement 
Network (THIN), a primary care electronic database 
that contains anonymised data on patients, practices, 
and consultations and is representative of the general 
UK population, with consultation and prescribing rates 
similar to national data.29 We used the same data extract 
that was previously used to evaluate which antibiotics 
are prescribed for different conditions in England.29 This 
extract was limited to English practices that participated 
in THIN and provided data for at least one full calendar 
year between 1 January 2013 and 31 December 2015. 
The prescription-diagnosis linkage is described in detail 
elsewhere.29 For the current analyses, we included only 
prescriptions for oral antibiotics linked to one of several 
indications: acute sinusitis, acute sore throat, acute 
cough and bronchitis, pneumonia, acute exacerbation 
of chronic obstructive pulmonary disease (COPD), 
acute otitis media, acute cystitis, acute prostatitis, 
pyelonephritis, cellulitis, impetigo, scarlet fever, and 
gastroenteritis. We excluded chronic and recurrent 
conditions, operationalised by excluding consultations 
explicitly coded as such and consultations where 
patients received antibiotics for a condition of the same 
body system (respiratory, urinary, gastrointestinal, 
or skin) in the 30 days before the current antibiotic 
prescription. In addition, we excluded prescriptions 
that were explicitly coded as a repeat prescription or 
were part of a sequence of prescriptions where the same 
antibiotic was prescribed every month for at least six 
months or covered more than 162 exposure days over 
a period of 180 days.29 Actual durations of antibiotic 
prescriptions for the 13 indications considered were 
compared with durations recommended in English 
guidance provided by Public Health England (PHE)—
using the PHE 2013 guidance for the main analysis (see 
table 1 and supplementary table S1): acute sinusitis,30 31 
acute sore throat,31 32 acute cough and bronchitis,31 33 
pneumonia,31 34 acute exacerbation of COPD,31 35 acute 
otitis media,31 36 acute cystitis,31 37 acute prostatitis,31 38 
pyelonephritis,31  39 cellulitis,31 40 impetigo,31 41 scarlet 
fever,31 42 and gastroenteritis.31 43
statistical analysis
For each indication we calculated the proportion of 
prescriptions longer than the recommended duration 
separately for children (<16 years) and for people 
aged 16 years or older, and by antibiotic where 
guidelines recommended different durations for 
particular drugs. Because guidelines recommend 
longer antibiotic courses to treat acute cystitis in males 
than females,31 37 we performed separate analyses for 
males and females for this condition. The cause of 
acute prostatitis in young men is often different44 from 
that in older men (sexually transmitted organisms 
versus mostly Enterobacteriaceae, respectively), and 
prescribers might fear chronic prostatitis more in older 
men. Therefore we evaluated three age groups for acute 
prostatitis: <35, 35-65, and >65 years old. In addition, 
for all conditions we performed a secondary analysis 
restricting to healthy patients, defined as those with 
no chronic kidney disease, COPD, asthma, coronary 
heart disease, immunosuppressive disease, or use of 
immunosuppressive drugs, systemic corticosteroids, 
or inhaled corticosteroids.11 45
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We used multiple imputations through chained 
equations using sequential regression trees to impute 
duration data that were missing in 10-20% of the 
consultations (see supplementary file 2 for more 
details).46 Confidence intervals were calculated using 
multiple imputation Wilson intervals, which have 
better properties than the usual multiple imputation 
confidence intervals, in particular always being 
bounded by zero and one.47 In sensitivity analysis, we 
restricted the analysis to data with no missing values.
In addition, we calculated the total number of excess 
antibiotic days, defined as the total number of days 
beyond the recommended duration in the guidelines.
All analyses were performed using R version 3.4.3 
(packages: “dplyr,” “ggplot2,” “mice,” “nlme”).
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked to 
advise on interpretation or writing up of results. Results 
will be disseminated to relevant patient communities 
through news media.
results
Between 2013 and 2015, 931 015 consultations for the 
13 included indications led to antibiotic prescriptions. 
This subset—which focused on common conditions, 
but excluded chronic and recurrent cases, repeat 
prescriptions, and antibiotic prophylaxis—covered 
about 20% of total antibiotics being prescribed (for any 
condition) during the study period. The most common 
indications were acute cough and bronchitis (386 972, 
41.6% of the included consultations), acute sore throat 
(239 231, 25.7%), acute otitis media (83 054, 8.9%), 
acute sinusitis (76 683, 8.2%), cellulitis (54 610, 
5.9%), and acute cystitis (53 010, 5.7%). Durations 
of antibiotic treatment for the included indications 
showed poor guideline adherence for several 
indications (fig 1 and supplementary figs S1-S8).
For all conditions grouped together, about 1.3 
million days beyond the durations recommended by 
guidelines (table 2), which remained the same during 
2013-15.
Most of the excess days were due to respiratory 
indications (table 2). Antibiotic treatments for 
respiratory indications, including otitis media, 
accounted for more than two thirds of the total 
prescriptions considered, and 80% or more of 
these treatment courses exceeded guideline 
recommendations (table 2). A notable exception was 
acute sinusitis, for which only 9.6% (95% confidence 
interval 9.4% to 9.9%) of prescriptions were longer 
than the seven days recommended by the PHE 
2013 guidance. For some indications, guidelines 
recommend longer durations for patients who are more 
unwell, such as those with pneumonia and a CRB65 
(confusion, respiratory rate, blood pressure, 65 years 
and older) score of 1 or 2, or a range of appropriate 
durations (supplementary table S1). A much smaller 
proportion of patients received antibiotic prescriptions 
exceeding these upper boundaries (table 2 and 
supplementary table S3).
When restricting to antibiotic prescriptions beyond 
the recommended durations, the median number 
of days beyond the guideline recommendation was 
2 (5th-95th centile 2-3 days) for acute cough and 
bronchitis, 2 (2-8) days for acute otitis media, and 3 
(1-7) days for acute sinusitis. This was 7 (3-8) days 
for cellulitis (using seven days as threshold), and 
for acute cystitis 4 (2-4) days for females and 7 (3-
32) days for males. In general, the tendency was to 
write prescriptions with a duration of five or seven 
days or multiples thereof (fig 1 and supplementary 
figs S1-S8). The peak at seven days, however, tended 
to be higher than for five days, even for conditions 
where a duration of five days is recommended. For 
conditions where guidelines recommend longer 
durations, the percentage of prescriptions beyond 
the recommendation was substantially lower than for 
conditions where guidelines recommend a relatively 
short duration.
For respiratory tract indications the total number of 
days of prescribed antibiotics beyond the recommended 
duration (approximately 1.1 million excess days in 
total) comprised a substantial proportion of the total 
number of days of antibiotics prescribed for these 
indications—for example, 29.5% for acute cough and 
bronchitis (table 2).
Fewer prescriptions exceeded recommended 
durations for non-respiratory tract indications, but 
still more than half of the antibiotic prescriptions were 
for longer than guidelines recommend for acute cystitis 
among females (54.6%, 95% confidence interval 54.1% 
to 55.0%) (table 2). Although guidelines recommend 
a shorter duration for fosfomycin,31 this did not affect 
our comparisons because this antibiotic was only used 
in two patients with acute cystitis. For acute prostatitis, 
the percentage of antibiotics prescribed for longer 
table 1 | antibiotic treatment durations for first line antibiotics recommended by Public 
Health england (PHe) guidance during 2013-15
indications
PHe recommendation for antibiotic prescription 
duration of first line antibiotics, 2013-15
Acute sinusitis 7 days
Acute sore throat 10 days
Acute cough and bronchitis 5 days
Community acquired pneumonia and CRB65=0 7 days
Community acquired pneumonia and CRB65=1 7-10 days
Acute exacerbation of COPD 5 days
Acute otitis media 5 days
Acute cystitis: non-pregnant females 3 days
Acute cystitis: males 7 days
Acute prostatitis 28 days
Pyelonephritis 7 days, except coamoxiclav, which is 14 days
Cellulitis 7 days, and continue for further 7 days if slow 
response
Impetigo 7 days
Scarlet fever 10 days*
Gastroenteritis 5-7 days
CRB65=confusion, respiratory rate, blood pressure, 65 years and older; COPD=chronic obstructive pulmonary 
disease.
*Not in PHE 2013 guidance; based on National Institute for Health and Care Excellence Clinical Knowledge 
Summaries guidance and PHE 2017 guidance.
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than the recommended duration was 12.5% (11.1% 
to 14.2%) using the recommendation of treatment 
for 28 days (table 2). When antibiotics are indicated 
for gastroenteritis, guidelines recommend prescribing 
antibiotics for 5-7 days. Setting the threshold at five 
days, 53.3% (50.8% to 55.8%) of prescriptions were 
for longer than guideline recommendations, whereas 
this percentage was 6.3% (5.2% to 7.7%) when using 
the seven day threshold (table 2).
The percentage of antibiotic prescriptions for which 
the actual duration was beyond the recommendation 
was much lower for pyelonephritis (18.0%, 16.3% to 
19.9%), acute cystitis among males (4.2%, 3.6% to 
4.9%), impetigo (9.9%, 9.4% to 10.4%), and cellulitis 
(13.9%, 13.6% to 14.2%), but this still translated into 
155 238 excess antibiotic days (table 2).
For acute prostatitis and acute cystitis among males, 
there appeared to be substantial under-treatment, 
with a substantial number of courses shorter than the 
guideline recommendations, with 52.3% below 28 
days and 26.0% below 14 days for acute prostatitis 
and 31.8% below seven days for acute cystitis among 
males (fig 1). In addition, some under-treatment was 
observed when using trimethoprim for pyelonephritis, 
antibiotics for impetigo, and penicillin V for scarlet 
fever (supplementary figs S5, S6, and S7, respectively).
There was no clear tendency to prescribe longer 
courses for children (<16 years) compared with adults 
(≥16 years) (supplementary table S2). Nevertheless, 
the percentage of prescriptions that were longer than 
recommended was higher among younger patients 
for acute cough and bronchitis (89.0% v 84.7%), 
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Fig 1 | Durations of antibiotic prescriptions for various indications
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acute otitis media (89.9% v 78.6%), impetigo (12.1% 
v 6.4%), pyelonephritis (27.2% v 17.7%), and 
gastroenteritis (70.7% v 51.0%).
Similar results were obtained when restricting the 
analyses to patients without relevant comorbidities 
(table 2 and table 3). After excluding patients with 
comorbidities and previous use of immunosuppressive 
drugs or inhaled or systemic corticosteroids, the 
percentage of prescriptions that were longer than 
recommended differed by 2% or less, with the 
estimates based on all patients.
When restricting the analyses to antibiotics only 
mentioned in the guidelines, results were generally 
similar to the analyses including all antibiotics 
(supplementary table S3). A notable exception 
was gastroenteritis. The percentage of antibiotic 
prescriptions longer than guidelines recommended 
became lower for gastroenteritis when only considering 
antibiotics mentioned in the guidelines (40.0% v 
53.3%, using a threshold of five days). In addition, for 
sore throat, pyelonephritis, and scarlet fever, longer 
prescriptions are recommended for specific antibiotics. 
In these cases, observed durations less frequently 
exceeded durations recommended in the guidelines 
compared with other antibiotics prescribed for the 
same condition (supplementary table S3). For most 
conditions, 75% or more of the prescribed antibiotics 
were mentioned in the guidelines for treatment of 
that condition (supplementary table S3). A notable 
exception was gastroenteritis, where only 12.8% 
of the patients were treated with the recommended 
antibiotic.
table 2 | Percentage of antibiotics with a duration exceeding guideline recommendations for all patients and antibiotics
recommended treatment duration 
(days) by condition no with condition
antibiotic prescriptions with duration exceeding 
recommendations excess days (% of 
total days)no % (95% ci)
Acute sinusitis:
 7 76 683 7384 9.6 (9.4 to 9.9) 39 422 (7.1)
Acute sore throat:
 5* 239 231 200 520 83.8 (83.7 to 84.0) 640 381 (35.0)
 10* 239 231 4972 2.1 (2.0 to 2.1) 72 001 (3.9)
Acute cough and bronchitis:
 5 386 972 331 257 85.6 (85.5 to 85.7) 805 051 (29.5)
Community acquired pneumonia:
 7† 952 77 8.1 (6.4 to 10.1) 744 (10.3)
 10† 952 32 3.4 (2.3 to 4.9) 535 (7.4)
Acute COPD exacerbation:
 5 12 067 10 742 89.0 (88.4 to 89.6) 26 732 (30.8)
Acute otitis media:
 5 83 054 71 750 86.4 (86.1 to 86.6) 193 262 (31.9)
Acute cystitis: females:
 3 48 734 26 591 54.6 (54.1 to 55.0) 99 321 (40.5)
Acute cystitis: males:
 7 4276 181 4.2 (3.6 to 4.9) 1541 (5.6)
Acute prostatitis:
 28 1838 231 12.5 (11.1 to 14.2) 206 (7.3)
Pyelonephritis:
 7‡ 1948 351 18.0 (16.3 to 19.9) 2135 (14.1)
 14‡ 1948 7 0.3 (0.1 to 0.9) 269 (1.8)
Cellulitis:
 7§ 54 610 7610 13.9 (13.6 to 14.2) 47 063 (11.2)
 14§ 54 610 424 0.8 (0.7 to 0.9) 6719 (1.6)
Impetigo:
 7 16 599 1646 9.9 (9.4 to 10.4) 13 948 (11.8)
Scarlet fever:
 5¶ 2350 1887 80.3 (78.5 to 82.0) 9808 (45.7)
 10¶ 2350 157 6.7 (5.7 to 7.9) 1493 (7.0)
Gastroenteritis:
 5** 1701 906 53.3 (50.8 to 55.8) 3071 (27.3)
 7** 1701 108 6.3 (5.2 to 0.7) 1260 (11.2)
COPD=chronic obstructive pulmonary disease.
*When antibiotics are indicated, Public Health England (PHE) 2013 guidance recommends 10 days when using penicillin V and five days when using 
clarithromycin for sore throat.
†PHE 2013 guidance recommends seven days for patients with a CRB65 (confusion, respiratory rate, blood pressure, ≥65 years) score of 0 and 7-10 
days in patients with a CRB65 score of 1.
‡PHE 2013 guidance recommends seven days when treating pyelonephritis with ciprofloxacin and 14 days when using coamoxiclav.
§For patients with cellulitis, PHE 2013 guidance recommends starting with seven days and in case of a slow response continuing for another seven days. 
The Clinical Knowledge Summaries (CKS) guidance (last revised July 2015) recommends a treatment duration of seven days, except for patients with 
known lymphoedema for whom antibiotics should be continued ≥14 days beyond first observation of clinical response.
¶Scarlet fever was not included in the PHE 2013 guidance. PHE 2017 guidance and CKS guidance recommend 10 days of treatment when using 
penicillin V. The CKS guidance recommends treating children with amoxicillin for 10 days in case penicillin V is not deemed suitable. For other antibiotics 
(clarithromycin or azithromycin) guidelines recommend a treatment duration of five days.
**Where patients with gastroenteritis are systemically unwell and campylobacter infection is suspected, a duration of 5-7 days is recommended by PHE 
2013 guidance.
 o
n
 6 M
arch 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l440 on 27 February 2019. Downloaded from 
RESEARCH
6 doi: 10.1136/bmj.l440 | BMJ 2019;364:l440 | the bmj
Sensitivity analysis restricting the analysis to data 
with no missing values gave similar results to the main 
analysis (supplementary table S4).
discussion
For most common infections treated in primary care, 
a substantial proportion of antibiotic prescriptions 
have durations exceeding those recommended 
in guidelines. This is most noticeable for most 
respiratory indications and acute cystitis among 
females. If all patients receiving antibiotics for the 
included indications received treatment for durations 
recommended by guidelines over the study period 
(three years in about 4.4% of the English population; 
included prescriptions captured around 20% of total 
antibiotic prescriptions in the included practices 
during the study period), this would equate to 1.1 
million fewer days of antibiotics for respiratory tract 
indications and 100 000 fewer days for acute cystitis 
among females. Our findings indicate substantial 
scope for reducing antibiotic prescribing through 
better adherence to recommended durations of 
antibiotic treatment. In contrast, the duration of 
antibiotic prescriptions for pyelonephritis, acute 
cystitis among men, impetigo, and cellulitis generally 
did not exceed guideline recommendations, with only 
4-18% of prescriptions exceeding them.
comparison with other studies
This study assessed the extent to which the duration of 
antibiotic prescriptions, for a wide range of common 
infections, follow guidelines in English primary care. In 
contrast with a recent US study only focusing on acute 
sinusitis,25 we were able to account for comorbidities 
and previous use of drugs that potentially influence 
the duration of prescriptions. We found similar 
results when restricting to healthy patients without 
comorbidities or past use of immunosuppressive drugs 
or corticosteroids, suggesting that comorbidities do 
not play a major part in the decision process about the 
duration of the antibiotic prescribed. Similarly, we did 
not find large differences in antibiotic prescriptions 
between children and adults. This provides further 
support for the argument that treatment durations 
are not increased because individual patient factors 
indicated a clinical need for prolonged treatment.
We only assessed whether the durations of antibiotic 
prescriptions followed guidelines and not whether 
antibiotics should have been completely avoided. 
Previous work showed that a substantial proportion of 
table 3 | Percentage of antibiotics with a duration exceeding guideline recommendations for patients without 
comorbidities or previous use of immunosuppressive drugs, inhaled corticosteroids, or systemic corticosteroids
recommended treatment duration for comorbidities 
when antibiotics indicated (days) no of patients
antibiotic prescriptions with duration exceeding 
 recommendations
no of prescriptions % (95% ci)
Acute sinusitis:
 7 51 206 4701 9.2 (8.9 to 9.5)
Acute sore throat:
 5 188 708 156 722 83.1 (82.9 to 83.2)
 10 188 708 4114 2.2 (2.1 to 2.3)
Acute cough and bronchitis:
 5 204 867 175 193 85.5 (85.4 to 85.7)
Community acquired pneumonia:
 7 434 30 6.8 (4.7 to 9.9)
 10 434 11 2.6 (1.3 to 4.9)
Acute COPD exacerbation*:
 5 5737 5116 89.2 (88.3 to 90.0)
Acute otitis media:
 5 69 217 60 170 86.9 (86.7 to 87.2)
Acute cystitis females:
 3 31 794 17 008 53.5 (52.9 to 54.0)
Acute prostatitis:
 28 1240 159 12.8 (11.0 to 14.8)
Pyelonephritis:
 7 1347 254 18.9 (16.8 to 21.2)
 14 1347 3 0.2 (0.06 to 0.9)
Cellulitis:
 7 26 041 3217 12.4 (12.0 to 12.8)
 14 26 041 206 0.8 (0.7 to 0.9)
Impetigo:
 7 13 457 1398 10.4 (9.9 to 10.9)
Scarlet fever
 5 2081 1673 80.4 (78.5 to 82.2)
 10 2081 142 6.8 (5.8 to 8.1)
Gastroenteritis:
 5 1193 628 52.7 (49.7 to 55.7)
 7 1193 78 6.5 (5.1 to 8.3)
COPD=chronic obstructive pulmonary disease.
*Only considered other comorbidities than COPD and ignored corticosteroid use.
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prescriptions for acute cough and bronchitis, acute otitis 
media, acute sinusitis, acute sore throat, and impetigo 
in primary care are unnecessary.11 Therefore, for these 
conditions the total number of days of unnecessary 
antibiotic use will be higher than estimated here. For 
example, if 77% of antibiotic prescriptions for acute 
sinusitis were inappropriate,11 the percentage of days 
of antibiotic treatment not following guidelines would 
increase from 7.1% to 81.1% for this indication. 
Antibiotics might also be unnecessary for community 
acquired pneumonia, for which it has been estimated 
that up to 25% of cases are caused by viruses without 
a bacterial coinfection.48 However, it can be difficult to 
distinguish between patients with community acquired 
pneumonia requiring antibiotics and those who can 
safely be treated without antibiotics in the primary care 
setting. Similarly, in suspected urinary tract infection, 
significant bacteriuria (>103) colony forming unit 
(CFU)/mL has been found in only 25-65% of patients 
aged less than 65 years given antibiotic treatment. In 
older adults, asymptomatic bacteriuria is common and 
does not require antibiotic treatment.11 49 50
For two of the antibiotic indications we studied, 
treatment was frequently prescribed for shorter 
durations than recommended—both urinary tract 
infections in men: acute cystitis and acute prostatitis. 
This could arise because prescribers appreciate that 
recommendations for these conditions are based on 
expert opinion and historical precedent rather than 
evidence, and that treatment durations for urinary tract 
infections in women have declined considerably in 
recent years. It needs to be established whether shorter 
treatment durations are effective for men with urinary 
tract infections, as this is a small but important patient 
population with a risk of harm from under-treatment. 
Notably, the conditions for which course durations 
tended to be less than recommended in the guidelines 
were those for which evidence supporting duration of 
treatment is weak (supplementary figs S5-S7).
In general, the preference seemed to be for 
antibiotic prescriptions with durations of five or 
seven days or multiples thereof, without a clear 
evidence base for this preference. The preference 
for such durations has been observed previously in 
other settings and depended more on local practice 
and subspecialty than on clinical features such as 
fever, comorbidities, and severity.51-53 In addition, 
for conditions where guidelines recommend longer 
durations, the percentage of prescriptions beyond 
the recommendation is substantially lower than for 
conditions where guidelines recommend a relatively 
short duration.
limitations of this study
One important limitation is that some antibiotic 
prescriptions may have been falsely linked to certain 
conditions in our study, because there is no automatic 
link between prescriptions and diagnoses in THIN.29 
Results were, however, similar when restricting the 
analyses to only antibiotics mentioned in the guidelines 
for each specific condition, which increases the chance 
that the antibiotic was being used for the condition of 
interest. Although we excluded complicated, recurrent 
infections that may require longer treatment, we were 
not able to account fully for patient factors that might 
underlie decisions to prolong treatment. We were 
also not able to explore clinician factors that could 
underlie deviation from recommended durations of 
antibiotic treatment. For some patients in some cases 
longer durations would be appropriate; however, no 
clear evidence exists about the percentage of patients 
who should legitimately receive longer prescriptions. 
Moreover, for some infections, such as acute sinusitis, 
recent evidence indicates that the duration of antibiotic 
treatment should be shorter instead of longer than the 
recommended durations in the PHE 2013 guidance 
(five and seven days, respectively).30
We were unable to account for the possibility that 
treatment durations for some patients are influenced 
by pack sizes, which may include more than the 
prescriber would like dispensed, or by protocolised 
durations set in electronic prescribing decisions. Pack 
size could result in unintended antibiotic overuse, 
whereas electronic based decisions might be expected 
to guide prescribers to recommended durations. Both, 
however, are system factors that could be addressed to 
help prescribers make more patient tailored decisions 
about minimum effective duration of treatment.
The evidence base for optimal durations of treatment 
for respiratory tract infections in primary care is 
relatively small27 28 54; although there is increasing 
evidence that lengths of antibiotic courses can safely 
be reduced for several conditions in primary care,18 27 
clinicians may lack confidence in guidelines around 
duration of antibiotic treatment.55 56 We were only 
able to measure prescribed antibiotics and cannot 
determine how often patients did not take or complete 
their prescribed course, previously estimated to be 
between one in 10 and one in four patients.57 58 We did 
not exclude or separately analyse acute cystitis among 
pregnant women, for whom guidelines recommend 
seven days rather than three days.31 However, because 
women are pregnant for a minority of their lifespan, 
only a small proportion of the total number of cases of 
acute cystitis occur among pregnant women, thereby 
limiting the impact on the overall estimates.
conclusion and implications
Although previous work has shown that antibiotic 
use can potentially be substantially reduced by not 
prescribing antibiotics when they are unnecessary,1 11 
this study shows that unnecessary exposure to 
antibiotics may also be substantially reduced by 
aligning the course length more with guidelines and 
best available evidence. Highlighting the magnitude 
of this issue is only a first step. We need a better 
understanding of why clinicians tend to prescribe 
antibiotic courses that are longer than guideline 
recommendations, especially for respiratory tract 
infections. Poor guideline adherence may result from 
several factors, including lack of awareness and 
scepticism of specific guideline recommendations.55 56 
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Moreover, the idea that shorter courses increase the 
risk of antibiotic resistance for common bacterial 
infections is not evidence based, but could—together 
with concerns about treatment failure due to 
undertreatment—make primary care doctors hesitant 
to prescribe shorter antibiotic courses in line with 
guidance. Understanding the reasons would enable 
the development of interventions and support tools 
that could increase adherence to the guidelines and 
reduce unnecessary exposure to antibiotics.
Overall, substantial reductions in antibiotic 
exposure can be accomplished by aligning duration of 
antibiotic prescriptions with guidelines.
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